For the quarter, sales from the Pharmaceutical Segment stood at Rs 165.30 crore and accounted for 57% of sales. PBIT from the same was down by 21% to Rs 16.40 crore and accounted for 42% of total.

For the quarter, sales from the Crop Protection Segment stood at Rs 126.97 crore and accounted for 43% of sales. PBIT from the same was up by 37% to Rs 22.23 crore and accounted for 58% of total.

OPM stood at 18.4% down by 190 bps thus restricting the OP growth to Rs 53.77 crore, up by 14% YoY basis. Other income was lower by 54% to Rs 0.39 crore. Interest cost was higher by 15% to Rs 13.06 crore. Depreciation was up by 25% to Rs 21.45 crore thus resulting in a flat PBT of Rs 19.65 crore. After providing for total tax of Rs 4.32 crore up by 33% YoY, PAT for Sep 17 quarter was down by 6% to Rs 15.33 crore.

Performance for the 6 months ended Sep 17

Net sales for H1 ended Sep 17 stood at Rs 554.98 crore, up by about 22% YoY.

For the six months, sales from the Pharmaceutical segment stood at Rs 326.23 crore and accounted for 58% of sales. PBIT from the same was up by 5% to Rs 40.99 crore and accounted for 56% of total.

For the six months, sales from the Crop Protection segment stood at Rs 232.74 crore and accounted for 42% of sales. PBIT from the same was up by 11% to Rs 31.80 crore and accounted for 44% of total.

OPM stood at 18.6% down by 140 bps thus restricting the OP growth to Rs 103.44 crore, up by 14% YoY basis. Other income was higher by 14% to Rs 105.41 crore. Interest cost was higher by 1% to Rs 24.75 crore. Depreciation was up by 18% to Rs 80.66 crore thus resulting in a 15% growth in PBT to Rs 37.95 crore. After providing for total tax of Rs 9.30 crore up by 77% YoY, PAT for H1 ended Sep 17 was up by 3% to Rs 28.65 crore.